title: [Delphi consensus on management of dyslipidaemia in patients with impaired glucose metabolism: Diana study].
abstract: OBJECTIVE
  The aim of the present study was to develop a multidisciplinary consensus based on the Delphi system to establish clinical recommendations for the management of dyslipidaemia when hyperglycaemia is present, and the relevant factors that should be taken into consideration when prescribing and monitoring treatment with statins.
  
  
  METHODS
  The questionnaire developed by the scientific committee included four blocks of questions about dyslipidaemia in patients with impaired glucose metabolism. The results of the first two blocks are presented here: a) management of dyslipidaemia; b) relevant factors that should be taken into consideration when prescribing and monitoring treatment with statins.
  
  
  RESULTS
  Among the 497 experts who participated in the study, an agreement of over 90% was attained for recommending screening for dyslipidaemia in patients with diabetes or pre-diabetes and/or cardiovascular disease or a family history and/or abdominal obesity and/or hypertension. There was a high degree of agreement that a statin is the lipid-lowering treatment of choice, and that it should be switched when side effects develop. Also, the choice of statin and dose should be made according to baseline LDL cholesterol levels, the target to achieve, and the possible drug-drug interactions.
  
  
  CONCLUSIONS
  The screening of dyslipidaemia is primarily conducted in patients with cardiovascular disease, or any major cardiovascular risk factor. When prescribing a statin, physicians mainly focus on the ability to reduce LDL cholesterol and the risk of drug interactions.
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: JPedrobotet@parcdesalutmar.cat.
authors.forename: Juan
authors.initials: J
authors.lastname: Pedro-Botet
authors.affiliation: Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, España.
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.affiliation: Centro de Salud Palleter, Castellón, España.
authors.forename: Vicente
authors.initials: V
authors.lastname: Pascual
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario, Universitat de Valencia, Valencia, España.
authors.forename: Juan F
authors.initials: JF
authors.lastname: Ascaso
authors.affiliation: Servicio de Nefrología, Hospital Clínic de Barcelona, Barcelona, España.
authors.forename: Aleix
authors.initials: A
authors.lastname: Cases
authors.affiliation: Cátedra-Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España.
authors.forename: Jesús
authors.initials: J
authors.lastname: Millán
authors.affiliation: Centro de Salud de Repélega, Portugalete, Vizcaya, España.
authors.forename: Adalberto
authors.initials: A
authors.lastname: Serrano
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pintó
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000209:etiology; D032921:Consensus; D003697:Delphi Technique; D050171:Dyslipidemias / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006943:Hyperglycemia / Q000150:complications*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D012307:Risk Factors; D011795:Surveys and Questionnaires
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D005947:Glucose
keywords: Alteraciones del metabolismo de la glucosa; Cardiovascular disease; Diabetes mellitus tipo 2; Enfermedad cardiovascular; Estatinas; Glucose metabolism disorders; Glycosilated heamoglobin; Hemoglobina glucosilada; Prevención; Prevention; Statins; Type 2 diabetes mellitus